Theravance Biopharma
Update in progressTBPH (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Theravance Biopharma, Inc. is a South San Francisco biopharmaceutical company that develops and commercializes medicines in the United States. Its approved product YUPELRI is a once-daily, nebulized muscarinic antagonist for COPD. The company is advancing Ampreloxetine, a once-daily norepinephrine reuptake inhibitor in Phase 3 for symptomatic neurogenic orthostatic hypotension in multiple system atrophy. It collaborates with Viatris to develop and commercialize revefenacin, including YUPELRI inhalation solution. Founded 2013.
Company score
- Sentiment
- 0.15
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.02
- Governance
- 0.03
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!